We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Encap Drug Delivery Adds New Commercial Product to Portfolio
News

Encap Drug Delivery Adds New Commercial Product to Portfolio

Encap Drug Delivery Adds New Commercial Product to Portfolio
News

Encap Drug Delivery Adds New Commercial Product to Portfolio

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Encap Drug Delivery Adds New Commercial Product to Portfolio"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Encap has spent the last few years building its development services capability and has state of the art manufacturing facilities based in Livingston (United Kingdom). The company has been successfully audited by the European MHRA and USA FDA and has over 70 staff totally dedicated to the liquid fill hard capsule technology.

The company has development and commercial contracts with a large number of pharmaceutical and biotech clients across the major pharmaceutical markets (Europe, USA and Japan) and the company is now benefiting from the progression of these products through the development phase and into commercial manufacture.

Dr Stephen Brown (CEO) commented that he was delighted to have secured the commercial manufacturing contract for a proprietary pharmaceutical product that is currently licensed in Europe and is transferring to Encap from the existing CDMO. ‘This is a large volume, licensed pharmaceutical and the award of this contract demonstrates that in addition to its excellent development services capability, the company is able to provide a best in class commercially competitive manufacturing service.’

Encap is working closely with its client to prepare for the successful launch of this and other pharmaceutical products in 2012.

Dr Brown indicated that the company had now firmly established its credentials as an excellent development services and drug delivery partner (now 50% of the company’s revenues) and is now well placed to continue the expansion of its commercial manufacturing business. The company currently manufactures 10 commercial products and following the expansion of the manufacturing facility in 2008, the company strategy will be to add further commercial products in the coming years. This includes highly potent compounds or those which require special handling as the company now has dedicated high containment facilities within its Livingston site.

Advertisement